Cargando…
The impact of interrupting enzyme replacement therapy in late-onset Pompe disease
BACKGROUND: Late-onset Pompe disease (LOPD) is a rare autosomal recessive disorder caused by mutations in the GAA gene, leading to progressive weakness of locomotor and respiratory muscles. Enzyme replacement therapy (ERT), administered every second week, has been proven to slow down disease progres...
Autores principales: | Wenninger, Stephan, Gutschmidt, Kristina, Wirner, Corinna, Einvag, Krisztina, Montagnese, Federica, Schoser, Benedikt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903209/ https://www.ncbi.nlm.nih.gov/pubmed/33625582 http://dx.doi.org/10.1007/s00415-021-10475-z |
Ejemplares similares
-
STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa
por: Gutschmidt, Kristina, et al.
Publicado: (2021) -
Nociceptive pain in adult patients with 5q-spinal muscular atrophy type 3: a cross-sectional clinical study
por: Sagerer, Elena, et al.
Publicado: (2022) -
Dyslexia and cognitive impairment in adult patients with myotonic dystrophy type 1: a clinical prospective analysis
por: Gutschmidt, K., et al.
Publicado: (2020) -
Evaluation of myotonometry for myotonia, muscle stiffness and elasticity in neuromuscular disorders
por: Lukas, Katharina, et al.
Publicado: (2023) -
Alglucosidase alfa: 5 years of experience in late-onset Pompe disease
por: Schoser, Benedikt
Publicado: (2013)